MILESTONE PHARMACEUTICALS IN (MIST) Stock Price & Overview
NASDAQ:MIST • CA59935V1076
Current stock price
The current stock price of MIST is 1.69 USD. Today MIST is down by -0.59%. In the past month the price decreased by -0.59%. In the past year, price decreased by -11.05%.
MIST Key Statistics
- Market Cap
- 143.937M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.83
- Dividend Yield
- N/A
MIST Stock Performance
MIST Stock Chart
MIST Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MIST. When comparing the yearly performance of all stocks, MIST is a bad performer in the overall market: 81.76% of all stocks are doing better.
MIST Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST may be in some trouble as it scores bad on both profitability and health.
MIST Earnings
MIST Forecast & Estimates
11 analysts have analysed MIST and the average price target is 6.73 USD. This implies a price increase of 298.34% is expected in the next year compared to the current price of 1.69.
MIST Groups
Sector & Classification
MIST Financial Highlights
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -2.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.11% | ||
| ROE | -282.97% | ||
| Debt/Equity | 2.74 |
MIST Ownership
MIST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.3 | 933.096B | ||
| JNJ | JOHNSON & JOHNSON | 20.88 | 586.064B | ||
| MRK | MERCK & CO. INC. | 22.3 | 285.388B | ||
| PFE | PFIZER INC | 8.91 | 151.312B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 121.598B | ||
| ZTS | ZOETIS INC | 16.69 | 49.875B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.92 | 26.593B | ||
| VTRS | VIATRIS INC | 5.39 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.24 | 11.634B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.093B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.204B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.893B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.47 | 4.144B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MIST
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Company Info
IPO: 2019-05-09
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 33
Phone: 15143360444
MILESTONE PHARMACEUTICALS IN / MIST FAQ
What does MILESTONE PHARMACEUTICALS IN do?
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Can you provide the latest stock price for MILESTONE PHARMACEUTICALS IN?
The current stock price of MIST is 1.69 USD. The price decreased by -0.59% in the last trading session.
Does MIST stock pay dividends?
MIST does not pay a dividend.
What is the ChartMill rating of MILESTONE PHARMACEUTICALS IN stock?
MIST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for MIST stock?
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).
Who owns MILESTONE PHARMACEUTICALS IN?
You can find the ownership structure of MILESTONE PHARMACEUTICALS IN (MIST) on the Ownership tab.